Citations

Mayo Clinic

Showing 10 of 108522 citations.

Spinal dural arteriovenous fistula with intramedullary cord hemorrhage
Schmidt, Kristen A. , Huang, Josephine F. , Black, David F. , Kaufmann, Timothy J. , Lanzino, Giuseppe , Kumar, Neeraj

Neurology Clinical Practice | December 8, 2014 | Volume: 4 | Issue: 6 | Pages: 486-489

10.1212/cpj.0000000000000062 Get It

Palliative Sedation and What Constitutes Active Dying
Strand, Jacob J. , Feely, Molly A., Kramer, Neha M. , Moeschler, Susan M. , Swetz, Keith M.

American Journal of Hospice and Palliative Medicine® | December 8, 2014 | Volume: 33 | Issue: 4 | Pages: 363-368

10.1177/1049909114561997 | PMID 25487783 Get It

We present the case of a 34-year-old woman with Klippel-Feil syndrome who developed progressive generalized dystonia of unclear etiology, resulting in intractable pain despite aggressive medical and surgical interventions. Ultimately, palliative sedation was required to relieve suffering. Herein, we describe ethical considerations including defining sedation, determining prognosis in the setting of an undefined neurodegenerative condition, and use of treatments that concurrently might prolong or alter end-of-life trajectory. We highlight pertinent literature and how it may be applied in challenging and unique clinical situations. Finally, we discuss the need for expert multidisciplinary involvement when implementing palliative sedation and illustrate that procedures and rules need to be interpreted to deliver optimal patient-centered plan of care.
Tourette syndrome deep brain stimulation: A review and updated recommendations
Schrock, Lauren E. , Woods, Douglas W. , Porta, Mauro, Servello, Domenico , Silburn, Peter A., Walker, Harrison C. , Shahed‐Jimenez, Joohi, Savica, Rodolfo , Klassen, Bryan T. , Foote, Kelly D. , Ackermans, Linda , Temel, Yasin , Changizi, Barbara Kelly , Lozano, Andrés M. , Auyeung, M., Kaido, Takanobu, Agid, Yves, Welter, Marie Laure, Khandhar, Suketu M., Pourfar, Michael , Walter, Benjamin L. , Juncos, Jorge L., Leckman, James F. , Neimat, Joseph A, Okun, Michael S. , Jimenez‐Shahed, Joohi , Mink, Jonathan W. , Visser-Vandewalle, Veerle E. R. M. , Foltynie, Thomas , Machado, André G. , Zhang, Jianguo , Hu, Wei , Mari, Zoltan K. , Auyeung, Man , Mogilner, Alon Y. , Gross, Robert E. , Kuhn, Jens , Okun, Michael S , Leckman, James F , Walter, Benjamin L , Jimenez-Shahed, Joohi , Welter, Marie‐Laure

Movement Disorders | December 8, 2014 | Volume: 30 | Issue: 4 | Pages: 448-471

10.1002/mds.26094 | PMID 25476818 Get It

Abstract Deep brain stimulation (DBS) may improve disabling tics in severely affected medication and behaviorally resistant Tourette syndrome (TS). Here we review all reported cases of TS DBS and provide updated recommendations for selection, assessment, and management of potential TS DBS cases based on the literature and implantation experience. Candidates should have a Diagnostic and Statistical Manual of Mental Disorders , Fifth Edition (DSM V) diagnosis of TS with severe motor and vocal tics, which despite exhaustive medical and behavioral treatment trials result in significant impairment. Deep brain stimulation should be offered to patients only by experienced DBS centers after evaluation by a multidisciplinary team. Rigorous preoperative and postoperative outcome measures of tics and associated comorbidities should be used. Tics and comorbid neuropsychiatric conditions should be optimally treated per current expert standards, and tics should be the major cause of disability. Psychogenic tics, embellishment, and malingering should be recognized and addressed. We have removed the previously suggested 25‐year‐old age limit, with the specification that a multidisciplinary team approach for screening is employed. A local ethics committee or institutional review board should be consulted for consideration of cases involving persons younger than 18 years of age, as well as in cases with urgent indications. Tourette syndrome patients represent a unique and complex population, and studies reveal a higher risk for post‐DBS complications. Successes and failures have been reported for multiple brain targets; however, the optimal surgical approach remains unknown. Tourette syndrome DBS, though still evolving, is a promising approach for a subset of medication refractory and severely affected patients. © 2014 International Parkinson and Movement Disorder Society
MYST3/CREBBP Rearranged Acute Myeloid Leukemia after Adjuvant Chemotherapy for Breast Cancer
Gupta, Arjun , Patnaik, Mrinal M. , Naina, Harris

Case Reports in Oncological Medicine | December 8, 2014 | Volume: 2014 | Issue: No issue available | Pages: 1-3

10.1155/2014/361748 | PMID 25548695 Get It

Although rare, clinicians and patients must be aware that therapy related malignancies, specifically acute myeloid leukemia (AML), can occur as a complication of adjuvant chemotherapy for breast cancer. Vigilance for signs and symptoms is appropriate. AML with t (8;16) is a specific translocation leading to formation of a fusion protein ( MYST3/CREBBP ). The MYST3/CREBBP AML tends to develop within 2 years of adjuvant chemotherapy, especially for breast cancer, without preceding myelodysplasia. It usually presents with disseminated intravascular coagulation and osteolytic lesions and has a poor prognosis despite aggressive resuscitation and therapy. With the increasing use of adjuvant chemotherapy for breast cancer, we are seeing a definite increase in the incidence of therapy related myelodysplastic syndromes and AML. One must keep this complication in mind while counseling and following up breast cancer patients who have received adjuvant chemotherapy. New osteolytic bone lesions in a patient with history of breast cancer do not necessarily mean metastatic disease and should be fully evaluated.
Editorial: expanding a narrow perspective on narrow calibre oesophagus in eosinophilic oesophagitis – authors' reply
Alexander, J, Katzka, David A.

Alimentary Pharmacology & Therapeutics | December 8, 2014 | Volume: 41 | Issue: 1 | Pages: 148-149

10.1111/apt.13016 | PMID 25483434 Get It

Ceftriaxone-Induced Acute Encephalopathy in a Peritoneal Dialysis Patient
Safadi, Sami , Mao, Michael, Dillon, John J, Mao, Michael A. , Dillon, John

Case Reports in Nephrology | December 7, 2014 | Volume: 2014 | Issue: No issue available | Pages: 1-4

10.1155/2014/108185 | PMID 25544915 Get It

Encephalopathy is a rare side effect of third and fourth generation cephalosporins. Renal failure and preexisting neurological disease are notable risk factors. Recognition is important as discontinuing the offending agent usually resolves symptoms. We present a case of acute encephalopathy in a patient with end stage renal disease (ESRD) treated with peritoneal dialysis (PD) who received intravenous ceftriaxone for peritonitis. This case illustrates the potential severe neurologic effects of cephalosporins, which are recommended by international guidelines as first-line antimicrobial therapy for spontaneous bacterial peritonitis.
Long-Term Outcome of Pyogenic Vertebral Osteomyelitis: A Cohort Study of 260 Patients
Kowalski, Todd J., Osmon, Douglas R. , Enzler, Mark J., Steckelberg, James M., Huddleston, P.M. , Mandrekar, Jayawant, Berbari, Elie F. , Mandrekar, Jayawant M, Gupta, Arjun , Nassr, Ahmad , Huddleston, Paul M

Open Forum Infectious Diseases | December 6, 2014 | Volume: 1 | Issue: 3 | Pages: No page available

10.1093/ofid/ofu107 | PMID 25734175 Get It

AbstractBackground. The long-term outcome of patients with pyogenic vertebral osteomyelitis (PVO) has not been fully assessed.Methods. We conducted a retrospective cohort study to describe the long-term outcome of PVO and to assess risk factors for treatment failure in patients evaluated at our institution between 1994 and 2002. Patients were observed until July 1, 2013.Results. Two hundred sixty patients with PVO were included in this study. Twenty-seven percent (70) of patients developed their infection after an invasive spinal procedure. Staphylococcus aureus accounted for 40% (103) of infections. Forty-nine percent (128) of patients underwent spinal surgery as part of their initial therapy. The median duration of parenteral antimicrobial therapy was 42 days (interquartile range, 38–53). The estimated 2-, 5-, and 10-year cumulative probability of treatment failure-free survival was 72%, 69%, and 69%, respectively. Seventy-five percent of patients who developed treatment failure did so within 4.7 months of diagnosis. Residual neurological defects and persistent back pain were seen in 16% and 32% of patients, respectively. In a multivariate analysis, longer duration of symptoms before diagnosis and having an infection with S. aureus were associated with increased risk of treatment failure.Conclusions. Increasing duration of symptoms and infection with S. aureus were associated with treatment failure in patients with PVO. Most treatment failures occurred early after initiation of treatment. Pyogenic vertebral osteomyelitis is associated with a high 2-year failure rate. Persistent neurological deficits and back pain are common after therapy.
Estrogen-Like Potentiation of Ghrelin-Stimulated GH Secretion by Fulvestrant, a Putatively Selective ER Antagonist, in Postmenopausal Women
Veldhuis, Johannes D. , Yang, Rebecca , Wigham, Jean, Erickson, Dana , Miles, John C. , Bowers, Cyril Y.

The Journal of Clinical Endocrinology & Metabolism | December 5, 2014 | Volume: 99 | Issue: 12 | Pages: E2557-E2564

10.1210/jc.2014-2633 | PMID 25210881 Get It

Context: Hyposomatotropism in healthy aging women reflects in part physiological estrogen (estradiol [E2]) depletion associated with menopause. Objective and Design: The purpose of this study was to test the hypothesis that low concentrations of endogenous E2 after menopause continue to drive GH secretion. Setting: The study was performed at the Mayo Center for Clinical and Translational Science. Participants: The participants were 24 postmenopausal women (aged 50–77 years with body mass index of 19–32 kg/m2). Interventions: This was a randomized, double-blind, placebo-controlled, parallel-cohort treatment study with placebo (PL) (n = 14) or the antiestrogen fulvestrant (FUL) (n = 10) for 3 weeks, followed by infusion of l-arginine with saline, GHRH, ghrelin, or both peptide secretagogues. Outcomes: GH concentrations were measured over 6 hours with 10-minute sampling and mass spectrometry measures of testosterone, E2, and estrone. Results: Concentrations of testosterone, E2, estrone, SHBG, IGF-I, LH, and FSH were not influenced by antiestrogen treatment. In contrast, GH rose from 0.096 ± 0.018 (PL) to 0.23 ± 0.063 μg/L (FUL, P = .033), and IGF-I binding protein type 3 (IGFBP-3) from 3.6 ± 0.18 to 4.0 ± 2.0 mg/L (P = .041). Conversely, prolactin fell from 7.1 ± 0.69 (PL) to 5.5 ± 0.57 μg/L (FUL) (P = .05), and IGF-I binding protein type 1 (IGFBP-1) fell from 44 ± 9.4 to 27 ± 4.3 μg/L (P = .048). Moreover, FUL vs PL potentiated mean GH responses to l-arginine/saline (P = .007), l-arginine/ghrelin (P = .008), and l-arginine/GHRH + ghrelin (P = .031), but not l-arginine/GHRH. Conclusion: The potent antiestrogen, FUL, amplifies fasting and secretagogue-driven GH secretion and IGFBP-3 concentrations in postmenopausal women without altering SHBG or sex steroid levels. FUL also suppresses prolactin and IGFBP-1, without altering IGF-I. Thus, a major antiestrogen mediates 3 actions of estrogen: agonism (GH), neutral effects (sex steroids), and estrogen antagonism (prolactin and IGFBP-1).
Research as Affect-Sphere: Towards Spherogenics
Iedema, Rick , Carroll, Katherine

Emotion Review | December 5, 2014 | Volume: 7 | Issue: 1 | Pages: 67-72

10.1177/1754073914544477 Get It

This article outlines the main tenets of affect theory and links these to Sloterdijk’s spherology. Where affect foregrounds prepersonal energies and posthuman impulses, spherology provides a lens for considering how humans congregate in constantly reconfiguring socialities in their pursuit of legitimacy and immunity. The article then explores the relevance of “affective spheres” for contemporary social science research. The article’s main argument here is that research of contemporary organisational and professional practices must increasingly be spherogenic, or seeking to build “affective spheres.” The basis of this argument are the in situ complexity and fast-changing nature of practices, and the increasing challenges involved in objectifying or ‘freezing’, and analysing or dissecting such practices. The article draws for its case study on a video-reflexive project conducted in a U.S. health service. The article concludes that the notion of research as spherogenics counterbalances the conventional methodological emphasis on a predetermined stance —whether neutral or political—in our construction and enactment of social science research.
Wireless control of intraspinal microstimulation in a rodent model of paralysis
Grahn, Peter J. , Lee, Kendall H. , Kasasbeh, Aimen, Mallory, Grant W., Hachmann, Jan T. , Dube, John R., Kimble, Christopher J., Lobel, Darlene A., Bieber, Allan J., Jeong, Ju Ho , Bennet, Kevin E. , Bieber, Allan, Luján, J. Luis

Journal of Neurosurgery | December 5, 2014 | Volume: 123 | Issue: 1 | Pages: 232-242

10.3171/2014.10.jns132370 | PMID 25479124 Get It

OBJECT Despite a promising outlook, existing intraspinal microstimulation (ISMS) techniques for restoring functional motor control after spinal cord injury are not yet suitable for use outside a controlled laboratory environment. Thus, successful application of ISMS therapy in humans will require the use of versatile chronic neurostimulation systems. The objective of this study was to establish proof of principle for wireless control of ISMS to evoke controlled motor function in a rodent model of complete spinal cord injury. METHODS The lumbar spinal cord in each of 17 fully anesthetized Sprague-Dawley rats was stimulated via ISMS electrodes to evoke hindlimb function. Nine subjects underwent complete surgical transection of the spinal cord at the T-4 level 7 days before stimulation. Targeting for both groups (spinalized and control) was performed under visual inspection via dorsal spinal cord landmarks such as the dorsal root entry zone and the dorsal median fissure. Teflon-insulated stimulating platinum-iridium microwire electrodes (50 μm in diameter, with a 30- to 60-μm exposed tip) were implanted within the ventral gray matter to an approximate depth of 1.8 mm. Electrode implantation was performed using a free-hand delivery technique (n = 12) or a Kopf spinal frame system (n = 5) to compare the efficacy of these 2 commonly used targeting techniques. Stimulation was controlled remotely using a wireless neurostimulation control system. Hindlimb movements evoked by stimulation were tracked via kinematic markers placed on the hips, knees, ankles, and paws. Postmortem fixation and staining of the spinal cord tissue were conducted to determine the final positions of the stimulating electrodes within the spinal cord tissue. RESULTS The results show that wireless ISMS was capable of evoking controlled and sustained activation of ankle, knee, and hip muscles in 90% of the spinalized rats (n = 9) and 100% of the healthy control rats (n = 8). No functional differences between movements evoked by either of the 2 targeting techniques were revealed. However, frame-based targeting required fewer electrode penetrations to evoke target movements. CONCLUSIONS Clinical restoration of functional movement via ISMS remains a distant goal. However, the technology presented herein represents the first step toward restoring functional independence for individuals with chronic spinal cord injury.